| Title | Pharmacology of the future – pharmacogenomics | |
| Authors | Z. Papadopoulou-Daifoti and E. Tiligada
Department of Experimental Pharmacology, Medical School, University of Athens, Athens, Greece |
|
| Citation | Papadopoulou-Daifoti, Z., Tiligada, E.: Pharmacology of the future – pharmacogenomics, Epitheorese Klin. Farmakol. Farmakokinet. 15(3): 143-146 (2001) | |
| Publication Date | Accepted for publication: 1 August 2001 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Pharmacology, informatics, drug design, pharmacogenomics, genetic polymorphism. | |
| Other Terms | review article | |
| Summary | Pharmacology, the science of drugs, has evolved through the centuries from mysticism to molecular sciences, guiding the human race through the struggle against disease prevention and therapy. Nowadays, informatics, genetics and genomics promise to effect profound changes in the approach to healthcare, by providing growing knowledge In drug discovery, early disease diagnosis, prevention and therapy, thus becoming the main challenge of the coming decade in pharmacology. | |
| References | 1. Drews J. (2000): Drug discovery: a historical perspective. Science, 287, 1960-1964.
2. Cragg G.M., Newman, D.J., Snader, K.M. (1997): Natural products in drug discovery and development. J. Nat. Prod., 60: 52-60. 3. Harvey A.L., Waterman P.G. (1998): The continuing contribution of biodiversity to drug discovery. Curr. Opin. Drug Discovery Dev. 1, 71-76, 4. Lesko L.J., Rowland M., Peck C.C., Blaschke T.F (2000): Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur. J. Pharmac. Sci. 10, iv-xiv. 5. Tait R.C, (1999): The application of molecular biology. Curr. Issues Mol. Biol. 1, 1-12. 6. Xue L, Bajorath J, (2000): Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen., 3, 363-372. 7. Ekins S., Wrighton S.A. (2001): Application of in silico approaches to predicting drug-drug interactions. J. Pharmacol. Toxicol. Methods, 45, 65-69. 8. Luscombe N.M., Greenbaum D., Gerstein M. (2001): What is bioinformatics? A proposed definition and overview of the field. Methods Inf. Med., 40, 346-358 9. Lazarou J., Pomeranz B.H., Corey P.N. (1998): Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 279, 1200-1205. 10. Lennard L., Van Loon J.A., Weinshilboum R.M. (1989): Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther., 46, 149-154. 11. Tan S., Hall I.P., Dewar J., Dow E., Lipworth B. (1997): Association between beta2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet, 350, 995- 999. 12. Krynetski E.Y., Evans W.E. (1998): Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet., 63, 11-16. 13. Spear B.B. (1999): Pharmacogenomics: Today, tomorrow, and beyond. Drug Benefit Trends, 11, 53-54. 14. Arranz M.J., Munro J., Birkett J., Bolonna A„ Mancama D., Sodhi M., Lesch K.P., Meyer J.F., Sham P., Collier D.A., Murray R.M., Kerwin R.W. (2000): Pharmacogenetic prediction of clonazepine response. Lancet, 355, 1615-1616. 15. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmolter J., Johne A., Cascorbi l., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. (2000): Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-giycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 97, 3473-3478. 16. Ingelman-Sundberg M. (2001): Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat. Res., 482, 11- 19. 17. Nanavaty U., Goldstein A.D., Levine S.J. (2001) Polymorphisms in candidate asthma genes. Am. J. Med. Sci., 321, 11-16. 18. Evans W.E., Relling M.V. (1999): Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491. 19. Sadee W. (1999): Pbarmacogenomics. Br. Med. J., 319, 1-4. 20. Destenaves B., Thomas F. (2000): New advances in pharmacogenomics. Curr. Opin. Chem. Biol., 4, 440-444. 21. McLeod H.L., Evans W.E. (2001): Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol., 41, 101-121. 22. Fijal B.A., Hall J.M., Witte J.S. (2000): Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial 2000. Cont. Clin. Trials, 21, 7-20. 23. Cichon S., Nothen M.M., Rietschel M., Propping P. (2000): Pharmacogenetics of schizophrenia. Am. J. Med. Genet., 97, 98-106. 24. Geller D.S., Farhi A., Pinkerton N„ Fradley M., Moritz M., Spitzer A., Meinke G., Tsai F.T., Sigler P.B., Litton R.P. (2000): Activating mineralocorttcoid receptor mutation 25. Sellers E.M., Tyndale R.F. (2000): Mimicking gene in hypertension exacerbated by pregnancy. Science, 289, defects to treat drug dependence. Ann. N.Y. Acad. Sci. 119-122. USA, 909, 233-246. |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2001 – ANNUAL SUBSCRIPTION 2001 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|